Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Additional Octreotide Therapy to Sirolimus Achieved a Decrease in Sirolimus-refractory Chylous Effusion Complicated with Lymphangioleiomyomatosis
Masashi NambaTakeshi MasudaTakashi NakamuraYasushi HorimasuShintaro MiyamotoTaku NakashimaHiroshi IwamotoKazunori FujitakaHironobu HamadaNoboru Hattori
Author information
JOURNAL OPEN ACCESS

2017 Volume 56 Issue 24 Pages 3327-3331

Details
Abstract

Recently, sirolimus, an inhibitor of mammalian target of rapamycin, was reported to decrease chylous effusion in patients with lymphangioleimyomatosis (LAM). We herein report a case of a 34-year-old woman with LAM who developed refractory chylothorax and chylous ascites during sirolimus therapy. In this case, to reduce chylous effusion, we administered octreotide, which is often used to control postoperative chylous effusion, in addition to the sirolimus therapy. This combination therapy reduced the chylothorax and chylous ascites. For patients with LAM, octreotide therapy in addition to sirolimus may be effective for treating sirolimus-refractory chylous effusion.

Content from these authors
© 2017 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top